Vivet Therapeutics

📣#VivetTherapeutics is headed to the land down under!📣 Join our Co-Founder and CSO, Dr Gloria Gonzalez-Aseguinolaza at the Australasian Gene and Cell Therapy Society (#ASGCT) Biennial Meeting in Sydney, Australia from 30 October – 1 November. Don't miss this excellent opportunity to listen👂in as Gloria provides insight into gene editing for the treatment of inherited liver disorders. 📢 Session 1: Gene and molecular therapies 🎤 Presentation Title: Gene editing for the treatment of inherited liver disorders 📅 Date: Wednesday 30 October 2024 🕘 Time: 9.50-10.30 AEDT 💬 Connect with🤝Gloria onsite to learn more about our diversified pipeline of novel and long-lasting # rAAV-based gene therapies for rare inherited liver metabolic disorders. 📲 Follow Vivet Therapeutics on LinkedIn and on X @ Vivet_tx to stay up to date with our latest developments! #CerebroTendinousXanthomatosis #CGT #GeneTherapy #AAVectors

💗Pink October💗   In collaboration with Courir POUR ELLES, Vivet Therapeutics participated in an 8km walk/run to raise #BreastCancer Awareness and Prevention.   Join #TeamVivet in the cause as we rack up steps👟for #CourirPourElles’ 💗Pink 💗Challenge during #PinkOctober.   Also known as ‘le Défi Rose’, the Challenge helps raise #BreastCancerAwareness and highlights the role a healthy lifestyle plays in #cancerprevention.   #RunForACause #TogetherWeCan #PreventionThroughSport

Connect with Co-Founder & CEO, Jean-Philippe Combal & Director of Regulatory Affairs & Quality Assurance, Annelise Mery - Brossel at the inaugural Cell & Gene Therapy Regulatory Affairs Summit presented by Hanson Wade Group, from 28 - 30 October in 🏦 Washington, D.C.! Get in touch to schedule a meeting with the team or you can find Jean-Philippe and Anne at the following presentations: 📅 Date: Tuesday 29 October 2024 🕘 Time: 9:00 am EDT 🔥 Fireside Chat: Overcoming Current & Future Regulatory Challenges in the Cell & Gene Therapy Field 📢 Jean-Philippe Combal 📅 Date: Tuesday 29 October 2024 🕘 Time: 13:45 pm EDT 🔥 Panel: Navigating Various Assigned Designations like Orphan, Prime, & More to Clarify Criteria & Distinctions 📢 Jean-Philippe Combal 📅 Date: Wednesday 30 October 2024 🕘 Time: 9:30 am EDT 🔥 Panel: Supercharging Regulatory CMC by Overcoming Challenges to Ensure Safe & Efficacious Advanced Therapies 📢 Annelise Brossel The #Summit brings together #CGT therapy regulatory experts comprised of C-Level Executives, Vice Presidents, and Directors of regulatory affairs and CMC to delve into all aspects of #CellandGeneTherapy regulation, from pre-IND to post-BLA, to benchmark best practices and prepare for all significant regulatory milestones.

Three years after his diagnosis, Travis is still learning to navigate life with Wilson disease, managing strict medication and lingering challenges. Despite losing his career and independence, he’s determined to raise awareness. Learn more: https://bit.ly/4duGKDo #WilsonDiseaseAwareness #PatientStory #VivetTherapeutics

📰 News alert 📰 Vivet Therapeutics to present three posters on its cerebrotendinous xanthomatosis (#CTX) program and novel AAV gene delivery platform at the European Society of Gene and Cell Therapy Annual Congress 2024, starting today in Rome, Italy.   Check out the findings from our diversified #genetherapy pipeline, using our precise, highly engineered, next-generation viral vectors and gene constructs at the 📅 dates and 🕘 times below:   Date and Time: Tuesday 22 October at 19:30-21:00 CEST Poster Title: Long-term metabolic, phenotypic, and neuropathological characterization of the Cyp27a1-/- mouse model of cerebrotendinous xanthomatosis  Poster Number: P0381 Presenter: Laia Trigueros Motos, Research Scientist at Vivet Therapeutics   Date and Time: Wednesday 23 October at 13:30-15:00 CEST Poster Title: S/MAR-Containing AAV Vectors Result in an Increase in AAV Episomes and a Reduction in AAV Integration Sites in a Mouse Model With a High Rate of Hepatocyte Proliferation  Poster Number: P0138 Presenter: Andrea Llanos Ardaiz, PhD Apprentice at Vivet Therapeutics   Date and Time: Thursday 24 October at 18:00-19:30 CEST Poster Title: Liver-directed gene therapy normalizes toxic bile acid metabolite levels in the blood and brain of mice with cerebrotendinous xanthomatosis  Poster Number: P0888 Presenter: Laia Trigueros Motos, Research Scientist at Vivet Therapeutics   #Vivet is committed to developing long-lasting AAV-based gene therapies for CTX and other rare inherited liver metabolic disorders to ultimately provide more effective treatment options for patients. Read the press release linked in the comments below📜   #ESGCT2024 #AAVGeneTherapy #GenomicMedicines #CGT #CellandGeneTherapy #GenomeEditing

Who's excited about the World Orphan Drug Congress Europe 2024🌍taking place in Spain from 22-25 October? With over 25 years of expertise in #drugdevelopment, our Head of Clinical Operations & Patient Advocacy Representative, Sonia VALERO, will join industry leaders on a panel 📢 to share valuable insights on the "Convergence on Rare Disease and Precision Medicine - a Real Drive on Drug Development.” 📅 Date: Wednesday 23rd October 2024 🕘 Time: 14:10 CEST 📍 Location: Theatre 5, Fira de Barcelona   The World Orphan Drug Congress Europe is the largest and most established #orphandrug & #raredisease event worldwide, bringing together experts from the start to finish of #orphandrugs. See you there! #WODCE #RareDiseases #PrecisionMedicine #Genetherapy 

🎓Are you attending the upcoming 2024 European Society of Gene and Cell Therapy (#ESGCT) Congress, from 22-25 October in Rome, Italy? Don’t miss the opportunity to meet the Vivet Therapeutics leadership team who will be participating in a jam-packed schedule at the event. 👂Listen in as our Co-Founder and CSO, Dr Gloria Gonzalez-Aseguinolaza deliberates on the latest developments in gene therapy for liver disease in an oral presentation and panel discussion. Also check out our three poster📜presentations presented by Research Scientist, Laia Trigueros and PhD Apprentice, Andrea Llanos Ardaiz. See details on where you can find the team in action in the full agenda here👉https://bit.ly/487E7Xh As a proud sponsor of #ESGCT2024, Vivet’s leadership team comprised of CEO Jean-Philippe Combal, COO Anne DOUAR, Senior Project Leaders Celine Bouquet and Veronica Ferrer and Principal Scientist Nicholas Weber will be in attendance to provide further information on #Vivet’s diversified recombinant AAV-based #genetherapy pipeline. #AAVGeneTherapy #GenomicMedicines #CellandGeneTherapy #GenomeEditing #CGT

Wilson disease affects entire families. Travis' father, James, retired only to become a full-time caregiver when Travis became bedridden. While treatments helped alleviate some of his symptoms, Wilson disease continues to affect every aspect of his life - and the lives of his family members. Learn more about Travis and his family: https://bit.ly/4duGKDo #Caregivers #RareDisease #GeneTherapy #VivetTherapeutics

Before his diagnosis, Travis’ life was thriving—until mood swings, tremors, and pain turned it upside down. After misdiagnosis and multiple hospital visits, doctors finally identified Wilson disease, a rare disorder. For patients like Travis, early diagnosis and care are critical. Vivet Therapeutics is working to change the future of Wilson disease treatment. Learn more at www.vivet-therapeutics.com. Read more about Travis: https://bit.ly/4duGKDo #WilsonDisease #GeneTherapy #MedicalInnovation #VivetTherapeutics

Engaging with the #wilsondisease community in person continues to be enlightening and inspirational. Kudos to the Wilson Disease Association for a successful annual conference. Inspired by patients, Onward and Upward! Sonia VALERO Lori McKenna Alice Williams Rhonda Rowland